NeurAxis, Inc. (NRXS)
| Market Cap | 15.16M |
| Revenue (ttm) | 2.69M |
| Net Income (ttm) | -8.45M |
| Shares Out | 7.22M |
| EPS (ttm) | -1.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,900 |
| Open | 2.068 |
| Previous Close | 2.131 |
| Day's Range | 2.068 - 2.160 |
| 52-Week Range | 1.990 - 3.780 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 20, 2025 |
About NRXS
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and cha... [Read more]
Financial Performance
In 2024, NeurAxis's revenue was $2.69 million, an increase of 9.18% compared to the previous year's $2.46 million. Losses were -$8.45 million, -42.21% less than in 2023.
Financial StatementsNews
NeurAxis, Inc. (NRXS) Q4 2024 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS) Q4 2024 Earnings Conference Call March 20, 2025 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chi...
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis Inc. Issues Letter to Shareholders
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis, Inc (NRXS) Q3 2024 Earnings Call Transcript
NeurAxis, Inc (NYSE:NRXS) Q3 2024 Results Conference Call November 12, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Ch...
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
Conference call will be held today, Tuesday, November 12 at 9:00 am ET Conference call will be held today, Tuesday, November 12 at 9:00 am ET
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chi...
NeurAxis Reports Second Quarter 2024 Financial Results
Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS) Q1 2024 Earnings Conference Call May 22, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief...
NeurAxis Reports First Quarter 2024 Financial Results
CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic a...
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ch...
NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ch...
NeurAxis Announces New Medical Policy Coverage in North Dakota
CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS) Q4 2023 Earnings Call Transcript April 9, 2024 4:30 PM ET Company Participants Ben Shamsian - IR, Lytham Partners Brian Carrico - CEO Tim Henrichs - CFO Operator Thank you ...
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
CARMEL, Ind., April 01, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...